Charles Lane, MD
Allergy & Immunology · Lynchburg, VANPI 1699983353
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,186,838 of the $1,413,721 with a category attached, or 84.0%. 33 manufacturers reported payments, led by AstraZeneca at 39.1% of the total. Among allergy & immunology clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 2,375 payments — averaging $595.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$553K
- Sanofi$299K
- Regeneron Healthcare Solutions, Inc.$257K
- Teva Pharmaceuticals USA, Inc.$117K
- GSK$98K
- Genentech USA, Inc.$55K
- plus $34K from 27 others
What the payments were for
- Consulting fees$56,4524%
- Speaking & faculty fees$1,186,83884%
- Travel & lodging$121,2379%
- Food & beverage$48,2683%
- Education$9270%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 835 | $552,842 |
| Sanofi | 380 | $299,079 |
| Regeneron Healthcare Solutions, Inc. | 392 | $256,941 |
| Teva Pharmaceuticals USA, Inc. | 166 | $117,369 |
| GSK | 190 | $98,020 |
| Genentech USA, Inc. | 138 | $55,131 |
| Amgen(2 entities) | 38 | $11,864 |
| Pfizer | 32 | $7,078 |
| Novartis | 43 | $5,889 |
| Optinose US, Inc. | 20 | $3,026 |
| Incyte Corporation | 4 | $1,783 |
| Blueprint Medicines Corporation | 8 | $1,460 |
| Genentech, Inc. | 5 | $511 |
| CSL Behring | 17 | $508 |
| Sanofi-aventis U.S. LLC | 9 | $450 |
| ARS Pharmaceuticals Operations, Inc. | 22 | $298 |
| Kaleo, Inc. | 16 | $252 |
| Grifols USA, LLC | 9 | $233 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $232 |
| Boehringer Ingelheim | 14 | $226 |
| Biocryst US Sales Co., LLC | 9 | $203 |
| Pharming Healthcare, Inc. | 3 | $66 |
| Alk-abello, Inc | 1 | $53 |
| Ionis Pharmaceuticals, Inc. | 2 | $37 |
| Aimmune Therapeutics, Inc. | 2 | $33 |
| Regeneron | 1 | $31 |
| Verona Pharma, Inc. | 1 | $23 |
| Shire North American Group Inc | 1 | $16 |
| Galderma Laboratories, L.p. | 1 | $15 |
| Merck | 1 | $14 |
| Biocryst Pharmaceuticals, Inc. | 1 | $13 |
| Mylan Specialty L.p. | 1 | $12 |
| Circassia Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DUPIXENT$495,693
- TEZSPIRE$308,437
- FASENRA$114,528
- AIRSUPRA$110,418
- NUCALA$93,367
- ProAir Digihaler$80,328
- AirDuo RespiClick$77,248
- ArmonAir Digihaler$77,248
- XOLAIR$52,889
- CINQAIR$33,234
- Xhance$2,610
- AYVAKIT$1,260
- BREZTRI$118
How this compares
$1,413,721 in reported general payments places this provider in the 95th percentile of 133 allergy & immunology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 44 | $178,661 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 34 | $29,436 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 37 | $24,258 |
| Breo ElliptaFluticasone/Vilanterol | 21 | $10,456 |
| Epinephrine | 62 | $10,058 |
| Arnuity ElliptaFluticasone Furoate | 32 | $7,925 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 11 | $5,306 |
| Azelastine Hcl | 123 | $4,122 |
| SymbicortBudesonide/Formoterol Fumarate | 15 | $3,747 |
| Wixela InhubFluticasone Propion/Salmeterol | 21 | $2,098 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 13 | $1,526 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 35 | $1,443 |
| Ipratropium Bromide | 36 | $1,346 |
| Montelukast Sodium | 145 | $1,324 |
| Fluticasone Propionate | 68 | $1,023 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta, Anoro Ellipta | $98,020 | $53,12398 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $552,842 | $28,00452 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 133 allergy & immunology providers in Virginia.
Other allergy & immunology in Lynchburg
- Robert SullivanLynchburg$7K
- Laura DziadzioLynchburg$6K
- Jacqueline Eghrari-SabetVienna$1M
- Eric KarlinWilliamsburg$522K
- Nicholas RiderRoanoke$227K
- Courtney BlairMc Lean$139K
- Andrew KimFredericksburg$104K
- Behnam DaghighLeesburg$99K
- Ananth ThyagarajanBurke$97K
- Larry BorishCharlottesville$92K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.